LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 29, 2019 –Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences” or the “Company”), a clinical-stage small molecules company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today the presentation of two scientific posters with new preclinical development in the treatment of pulmonary arterial hypertension (“PAH”) at the American Heart Association (“AHA”) 2019 Annual Meeting. The conference will take place on November 16-18, 2019 in Philadelphia, PA.
“In collaboration with Montreal Heart Institute, we are pleased to present data showing significant activity of PBI-4050 in PAH, and also in combination with Valsartan in group II PH associated with left heart disease, with currently no therapy approved for prevention or treatment of group II PH” stated Kenneth Galbraith, Chief Executive Officer.
PBI-4050 Reduces Angio-proliferative Pulmonary Arterial Hypertension: Decreased Human Pulmonary Artery Smooth Muscle Cell Proliferation and Microvascular Endothelial Cell Endoplasmic Reticulum Stress
Poster # : 2253
Session: Markers and Outcomes in Pulmonary Hypertension I
Location: Zone 2, Science and Technology Hall, Level 2, Halls A-D, Pennsylvania Convention Center
Date & Time: Saturday, November 16, 2019 – 1:30 pm
Presentation details: Board # 2253, Presentation # Sa2253, 11/16/2019 1:30:00 PM - 11/16/2019 2:00:00 PM
Transcriptomics of Lung Molecular Remodeling in Pulmonary Hypertension Due to Left Heart Disease: Benefits of Combined PBI-4050/Valsartan Therapy
Poster #: 1140
Session: Functional Studies of Cardiovascular Disease
Location: Zone 1, Science and Technology Hall, Session number: GE.APS.04
Date & Time: Monday, November 18, 2019, 1:30 pm - 2:00 pm
Presentation details: Board # 1140, Presentation #Mo1140, 11/18/2019 1:30:00 PM-11/18/2019 2:00:00 PM
About Liminal BioSciences Inc.
Liminal BioSciences (www.liminalbiosciences.com) is an innovative biopharmaceutical company with a broad pipeline of small molecule therapeutics under development to treat unmet needs in patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. Liminal BioSciences’ research involves the study of several G-protein-coupled-receptors, GPR40, GPR84 and GPR120, known as free fatty acid receptors (FFAR’s). These drug candidates have a novel mechanism of action as agonist ("stimulator") of GPR40 and GPR 120, and antagonist ("inhibitor") of GPR84. Our lead drug candidate, PBI-4050, is expected to enter Phase 3 clinical studies for the treatment of Alström Syndrome after further consultation and approval by the FDA and EMA. A second drug candidate, PBI-4547, is currently in a Phase 1 clinical study.
Liminal BioSciences has also leveraged its lengthy experience in bioseparation technologies through its wholly-owned subsidiary Prometic Bioproduction Inc. to isolate and purify biopharmaceuticals from human plasma. Our lead plasma-derived therapeutic product is RyplazimTM (plasminogen) for which the Company expects to file a BLA with the US FDA in the first half of 2020 seeking approval to treat patients with congenital plasminogen deficiency. The Company also operates a contract development and manufacturing operation in the United Kingdom, deriving revenue through sales of affinity chromatography media, Prometic Bioseparations Ltd.
Liminal BioSciences has active business operations in Canada, the United States, Isle of Man and the United Kingdom.
Forward Looking Statement
This presentation contains forward-looking statements about Liminal BioSciences’ objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Liminal BioSciences’ ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Liminal BioSciences’ to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in the Annual Information Form for the year ended December 31, 2018, under the heading "Risks and Uncertainties related to Liminal BioSciences’ Business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
For further information please contact: